Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer January 13, 2021 – Posted in: Tiziana Life Sciences (TILS)

13th January, 2021 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer. Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist…

Tiziana Life Sciences – Initiation of Clinical Trial for COVID-19 Patients in Brazil November 2, 2020 – Posted in: Tiziana Life Sciences (TILS)

2nd November, 2020 Tiziana Life Sciences PLC (“Tiziana” or “the Company”) Tiziana Announces Initiation of Clinical Trial for COVID-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody London/New York, 2 November 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces initiation of a collaborative clinical study investigating nasally administered Foralumab either alone or in…

Tiziana Life Sciences – Interim Results for Six Months ended 30th June 2020 September 30, 2020 – Posted in: Uncategorized

30th September, 2020 Tiziana Life Sciences plc (“Tiziana” or “the Company”) Interim Results for the Six Months Ended 30 June 2020 Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA), a biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases today announces its interim results…

Tiziana Life Sciences – Bloomberg interview September 25, 2020 – Posted in: Tiziana Life Sciences (TILS)

25th September, 2020 Tiziana Life Sciences Plc (“Tiziana” or the “Company”) Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced an interview with Dr. Kunwar Shailubhai, CEO, will air on The RedChip Money Report television program. The interview will air Sunday, 27 September 2020,…

Tiziana Life Sciences – Issue of Equity & Total Voting Rights September 21, 2020 – Posted in: Tiziana Life Sciences (TILS)

21st September, 2020 Tiziana Life Sciences Plc (“Tiziana” or the “Company”) Issue of Equity and Total Voting Rights Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and issued 281,250 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid at a price of 128 pence per share in…

Tiziana Life Sciences – Clinical Study for September 17, 2020 – Posted in: Tiziana Life Sciences (TILS)

17/09/2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil Nasal Adminsteration of Foralumab is a potentially transformative approach for treating patients with COVID-19. New York/London, September 17, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious…

Tiziana Life Sciences – Demerger of StemPrintER – Posted in: Tiziana Life Sciences (TILS)

16/09/2020 Tiziana Life Sciences Plc (“Tiziana” or the “Company”) Demerger of StemPrintER and Distribution in Specie Proposed capital reduction and notice of General Meeting Tiziana Life Sciences Plc (LSE: TILS, NASDAQ: TLSA) a biotechnology company focussed on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that, following a strategic review of its clinical trial programs and core focus, it intends to demerge its StemPrintER and SPARE genomics-based personalised medicine business into a separate…

Tiziana Life Sciences – TR1 August 28, 2020 – Posted in: Tiziana Life Sciences (TILS)

28th August, 2020 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Tiziana Life Sciences PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for the notification (please mark the…

Tiziana Life Sciences – Amended ADS Registration Statement – Posted in: Tiziana Life Sciences (TILS)

28th August, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Life Sciences Clarifies Reason for Filing an Amended ADS Registration Statement ADS Registration Statement filed in order to Increase Capacity under the ADS Facility to Exchange Ordinary Shares for ADSs Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced the clarification of…

(No title) August 27, 2020 – Posted in: Tiziana Life Sciences (TILS)

27th August, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Life Sciences CEO Updates Shareholders on its Patent Portfolio, Clinical Pipeline, and Strategy in an Exclusive Interview Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced that an interview with its CEO and CSO Dr. Kunwar Shailubhai is now available. In the interview,…